This $20 Pill Just Exposed How Broken Our Healthcare System Really Is (And Made a CEO Very Rich)
Look, I know we all love a good story about the little guy sticking it to Big Pharma. We want the underdog to win, the CEO to get dragged, and the price of insulin to magically drop to the price of a mediocre burrito. But reality, as always, has other plans. And by "other plans," I mean it just handed us a masterclass in American healthcare that is so dystopian it makes *The Handmaid’s Tale* look like a budgeting seminar.
So, grab your outrage boner and your three-figure copay, because we’re talking about the $20 miracle drug that costs $20… unless your insurance company touches it.
The drug in question is Colchicine. Sounds fancy, right? It’s not. It’s literally a chemical extracted from the autumn crocus, a flower that has been used to treat gout since the Byzantine Empire was still figuring out how to make a decent mosaic. It’s ancient. It’s off-patent. And for decades, it cost about a nickel to make. You could buy a bottle for $10 at your local pharmacy and be on your merry way, hobbling slightly less aggressively.
Then, in 2009, the FDA decided to flex and create this thing called the "single-source" status for old, unapproved drugs. The idea was to incentivize companies to do the boring, expensive safety trials that nobody had ever bothered to do for these ancient meds. In exchange for actually proving the drug works (which, surprise, it did), the company gets a period of market exclusivity. Basically, a monopoly.
Enter Takeda Pharmaceuticals. They bought the rights to Colchicine, rebranded it as "Colcrys," and kicked off the single greatest price gouging operation this side of an EpiPen. Overnight, the price of Colchicine went from "loose change in your couch" to $4.85 per pill. That’s a 4,000% increase. For a drug that was literally a weed.
But here’s where the story gets spicy, and by "spicy," I mean it feels like getting waterboarded with your own health insurance denial letter. The internet is currently losing its goddamn mind over a new report from the nonprofit group Patients for Affordable Drugs. They found that while the cash price for a 30-day supply of Colchicine is still a manageable $20 at places like Costco (yes, the hot dog place), the price that insurance companies and their pharmacy benefit managers (PBMs) are paying is somehow *higher*.
Think about that for a second. The uninsured peasant paying cash gets the $20 deal. The person with "good" insurance? They’re paying a $35 copay and their insurance is getting billed $300 for the same bottle. It’s the opposite of a bulk discount. It’s a "you have coverage" tax.
This is not a glitch. This is the feature.
We have created a system so deeply, profoundly broken that the only way to get a fair price is to pretend you don’t have insurance. You are literally financially punished for having a PPO. The entire structure is a Rube Goldberg machine designed to funnel money from your paycheck, through your employer, through the insurance company, through the PBM, and into the pockets of a few executives who have convinced themselves they are "job creators."
Let’s break down the cast of villains because we need to keep track of who to scream at.
First, we have the PBMs. These are the faceless middlemen that your insurance company hires to "negotiate" drug prices. They are the wizard behind the curtain, except the wizard is just a guy in a suit who adds a hidden fee to every single transaction. They take a cut of the list price. So, the higher the list price, the more money they make. They have zero incentive to lower prices. In fact, their entire business model depends on keeping prices artificially inflated. It’s like paying a hostage negotiator a percentage of the ransom.
Then you have the insurance companies. They love this because they can blame the PBMs while still collecting your premiums. Your copay goes up? "Sorry, it’s the drug company." Your deductible is $8,000? "Blame the prescription costs." It’s a beautiful, circular firing squad where the only person getting shot is you.
And finally, the drug companies. They aren’t innocent. Takeda literally lobbied the FDA to block cheaper generic versions of Colchicine from coming to market, using every legal loophole and patent extension they could find. They spent millions on lawyers to make sure you couldn’t buy the $10 version of a flower extract.
The result is a $20 pill that costs $300. A drug that was discovered before the invention of the steam engine is now a multi-billion dollar industry.
The Reddit comments on this are, predictably, a beautiful trainwreck. One user on r/medicine summed it up perfectly: "The American healthcare system isn't a system. It's a protection racket with a 401k plan."
And they are right. We have normalized the idea that you should have to choose between treating your chronic pain and paying your rent. We have accepted that a 4,000% price increase is just "business." We have watched as our politicians, from both parties, take millions in campaign contributions from these same companies and then hold a "press conference" about lowering drug prices that is about as effective as using a squirt gun to put out a wildfire.
The Colchicine story is not an outlier. It’s the template. It’s happening with insulin. It’s happening with asthma inhalers. It’s happening with EpiPens. It’s happening with every drug that has been on the market for more than 20 years.
The solution is simple, which is why it will never happen. We need national drug price negotiation. We need to ban the PBM kickback system. We need to allow Medicare to use its massive purchasing power to tell a company, "You can sell
Final Thoughts
As a journalist who's covered the pharmaceutical beat for decades, I've seen how prescription drugs are a double-edged sword: they can extend life and ease suffering, yet the very system that delivers them is often warped by profit motives and opaque lobbying. The real story here isn't just about molecules and trials, but about trust—once broken by price gouging or hidden side effects, it's nearly impossible to rebuild. Ultimately, the prescription drug landscape will only improve when we demand transparency as loudly as we demand cures.